MX2019006640A - Fenitoina topica para el uso en el tratamiento del dolor neuropatico periferico. - Google Patents
Fenitoina topica para el uso en el tratamiento del dolor neuropatico periferico.Info
- Publication number
- MX2019006640A MX2019006640A MX2019006640A MX2019006640A MX2019006640A MX 2019006640 A MX2019006640 A MX 2019006640A MX 2019006640 A MX2019006640 A MX 2019006640A MX 2019006640 A MX2019006640 A MX 2019006640A MX 2019006640 A MX2019006640 A MX 2019006640A
- Authority
- MX
- Mexico
- Prior art keywords
- phenytoin
- neuropathic pain
- peripheral neuropathic
- neuropathies
- topical
- Prior art date
Links
- 208000004296 neuralgia Diseases 0.000 title abstract 4
- 230000002093 peripheral effect Effects 0.000 title abstract 4
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 title abstract 3
- 208000021722 neuropathic pain Diseases 0.000 title abstract 3
- 229960002036 phenytoin Drugs 0.000 title abstract 3
- 230000000699 topical effect Effects 0.000 title abstract 2
- 206010036105 Polyneuropathy Diseases 0.000 abstract 2
- 201000001119 neuropathy Diseases 0.000 abstract 2
- 230000007823 neuropathy Effects 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 229960002790 phenytoin sodium Drugs 0.000 abstract 2
- 230000007824 polyneuropathy Effects 0.000 abstract 2
- FJPYVLNWWICYDW-UHFFFAOYSA-M sodium;5,5-diphenylimidazolidin-1-ide-2,4-dione Chemical compound [Na+].O=C1[N-]C(=O)NC1(C=1C=CC=CC=1)C1=CC=CC=C1 FJPYVLNWWICYDW-UHFFFAOYSA-M 0.000 abstract 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 abstract 1
- 208000007920 Neurogenic Inflammation Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 abstract 1
- 208000010261 Small Fiber Neuropathy Diseases 0.000 abstract 1
- 206010073928 Small fibre neuropathy Diseases 0.000 abstract 1
- 230000003376 axonal effect Effects 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000002458 infectious effect Effects 0.000 abstract 1
- 208000019382 nerve compression syndrome Diseases 0.000 abstract 1
- 208000017692 primary erythermalgia Diseases 0.000 abstract 1
- 239000012049 topical pharmaceutical composition Substances 0.000 abstract 1
- 230000000472 traumatic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención se refiere a composiciones farmacéuticas que contienen fenitoína o fenitoína sódica para usarse en el alivio del dolor tópico. Dicho uso de la composición farmacéutica de la invención reduce el dolor neuropático periférico. Las composiciones farmacéuticas tópicas de la invención que contienen fenitoína o fenitoína sódica, sorprendentemente reducen el dolor neuropático periférico considerablemente, especialmente y preferiblemente en condiciones o enfermedades caracterizadas por un grado bajo a moderado de inflamación neurogénica periférica, tales como neuropatía de fibra pequeña, neuropatía diabética, polineuropatía axonal idiopática crónica, neuralgia postherpética, neuralgia del trigémino, polineuropatía inducida por quimioterapia, neuropatías traumáticas, neuropatías por compresión y neuropatías infecciosas en remisión, según la invención.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL2017931 | 2016-12-06 | ||
| PCT/NL2017/050814 WO2018106107A1 (en) | 2016-12-06 | 2017-12-06 | Topical phenytoin for use in the treatment of peripheral neuropathic pain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019006640A true MX2019006640A (es) | 2019-08-01 |
Family
ID=57796933
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019006640A MX2019006640A (es) | 2016-12-06 | 2017-12-06 | Fenitoina topica para el uso en el tratamiento del dolor neuropatico periferico. |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US11285099B2 (es) |
| EP (1) | EP3551166B1 (es) |
| JP (1) | JP7264813B2 (es) |
| CN (1) | CN110248644A (es) |
| AU (1) | AU2017371467B2 (es) |
| BR (1) | BR112019011743A2 (es) |
| CA (1) | CA3046055A1 (es) |
| CL (1) | CL2019001550A1 (es) |
| DO (1) | DOP2019000156A (es) |
| EA (1) | EA201991341A1 (es) |
| FI (1) | FI3551166T3 (es) |
| IL (1) | IL267114B2 (es) |
| MA (1) | MA51978A (es) |
| MX (1) | MX2019006640A (es) |
| PH (1) | PH12019550093A1 (es) |
| UA (1) | UA125040C2 (es) |
| WO (1) | WO2018106107A1 (es) |
| ZA (1) | ZA201906473B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12005034B2 (en) | 2017-04-25 | 2024-06-11 | Algotherapeutix | Topical pharmaceutical composition comprising at least amitriptyline, for the treatment of peripheral neuropathic pain |
| WO2021043673A1 (en) | 2019-09-02 | 2021-03-11 | Syddansk Universitet | P-gp inducers as protectors against chemotherapy-induced side effects, such as peripheral neuropathy (cipn) and hair loss |
| CN114681340A (zh) * | 2022-04-13 | 2022-07-01 | 肌赋萃生物科技(上海)有限公司 | 一种含有脂质包裹稳定技术的脂质屏障修复护肤品及其制备方法 |
| WO2024120461A1 (zh) * | 2022-12-09 | 2024-06-13 | 荣昌生物制药(烟台)股份有限公司 | Cyp3a4/5诱导剂在治疗或缓解周围神经病变中的应用 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5571521A (en) | 1984-01-16 | 1996-11-05 | Lasker; Sigmund E. | Composition containing silver ammonium phenytoin complex and a phenytoin and use of said composition |
| JPH0772190B2 (ja) * | 1985-02-26 | 1995-08-02 | エーザイ株式会社 | ヒダントイン誘導体 |
| JP3031973B2 (ja) | 1990-08-16 | 2000-04-10 | 富士レビオ株式会社 | フェニトイン誘導体 |
| US6113921A (en) * | 1993-03-23 | 2000-09-05 | Pharmos Corp. | Topical and transdermal delivery system utilizing submicron oil spheres |
| CN1046199C (zh) * | 1994-12-13 | 1999-11-10 | 凌吉安 | 复方消炎止痛霜剂 |
| AU4078897A (en) | 1996-08-23 | 1998-03-06 | Algos Pharmaceutical Corporation | Anticonvulsant containing composition for treating neuropathic pain |
| WO2001000191A2 (en) * | 1999-06-23 | 2001-01-04 | Warner-Lambert Company | Use of fosphenytion for the treatment of acute neuropathic pain |
| US20040191276A1 (en) | 1999-11-30 | 2004-09-30 | Cutispharma, Inc. | Compositions and kits for compounding pharmaceuticals |
| RU2262922C2 (ru) * | 2001-05-15 | 2005-10-27 | Уорнер-Ламберт Компани Ллс | Способ прессования для получения лекарственной формы фенитоина натрия |
| US7687080B2 (en) | 2002-11-25 | 2010-03-30 | Taraxos Inc. | Treatment of neuropathy |
| WO2006013084A1 (en) * | 2004-08-03 | 2006-02-09 | Royal College Of Surgeons In Ireland | Phenytoin formulations, and uses thereof in wound healing |
| US20060034910A1 (en) * | 2004-08-09 | 2006-02-16 | Sanjay Patel | Pharmaceutical composition for extended release of phenytoin sodium |
| CN101069692B (zh) * | 2006-05-08 | 2011-04-20 | 范敏华 | 含积雪草总甙的药物制剂及其制备方法 |
| WO2008079727A2 (en) | 2006-12-22 | 2008-07-03 | Allergan, Inc. | Compositions comprising an pan-alpha-2 receptor agonist and an anticonvulsant for treating chronic pain |
| EP2286828B1 (en) * | 2008-04-14 | 2016-05-18 | National University Corporation Nagoya University | Improving agent for neuropathic pain |
| AU2009269129B2 (en) * | 2008-06-30 | 2015-08-20 | Afgin Pharma, Llc | Topical regional neuro-affective therapy |
| CA2738468A1 (en) | 2008-09-27 | 2010-04-01 | Taraxos Inc. | Topical formulations for treatment of neuropathy |
| KR101271219B1 (ko) * | 2011-01-27 | 2013-06-07 | 광주과학기술원 | 신규한 하이단토인 유도체 및 이의 용도 |
| JP5512891B2 (ja) | 2011-06-20 | 2014-06-04 | 久光製薬株式会社 | リドカイン含有パップ剤 |
| US20130184351A1 (en) | 2011-12-21 | 2013-07-18 | Jar Laboratories | Lidocaine patch and methods of use thereof |
| US9345689B2 (en) * | 2012-05-18 | 2016-05-24 | Gruenenthal Gmbh | Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N, N-dimethyl-4-phenyl-4,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and an anticonvulsant |
| US20160303203A1 (en) * | 2013-12-09 | 2016-10-20 | Keshav Malshe | Compositions and methods for the treatment of wounds |
| CN106075556A (zh) | 2016-06-02 | 2016-11-09 | 四川奎星医用高分子制品有限责任公司 | 含有促进伤口愈合药物的医用复合壳聚糖凝胶 |
-
2017
- 2017-12-06 FI FIEP17817927.1T patent/FI3551166T3/fi active
- 2017-12-06 US US16/467,179 patent/US11285099B2/en active Active
- 2017-12-06 JP JP2019531112A patent/JP7264813B2/ja active Active
- 2017-12-06 UA UAA201907615A patent/UA125040C2/uk unknown
- 2017-12-06 BR BR112019011743A patent/BR112019011743A2/pt active Search and Examination
- 2017-12-06 CA CA3046055A patent/CA3046055A1/en active Pending
- 2017-12-06 IL IL267114A patent/IL267114B2/en unknown
- 2017-12-06 MA MA051978A patent/MA51978A/fr unknown
- 2017-12-06 WO PCT/NL2017/050814 patent/WO2018106107A1/en unknown
- 2017-12-06 AU AU2017371467A patent/AU2017371467B2/en active Active
- 2017-12-06 EP EP17817927.1A patent/EP3551166B1/en active Active
- 2017-12-06 MX MX2019006640A patent/MX2019006640A/es unknown
- 2017-12-06 EA EA201991341A patent/EA201991341A1/ru unknown
- 2017-12-06 CN CN201780082443.1A patent/CN110248644A/zh active Pending
-
2019
- 2019-06-06 DO DO2019000156A patent/DOP2019000156A/es unknown
- 2019-06-06 CL CL2019001550A patent/CL2019001550A1/es unknown
- 2019-06-06 PH PH12019550093A patent/PH12019550093A1/en unknown
- 2019-10-01 ZA ZA2019/06473A patent/ZA201906473B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DOP2019000156A (es) | 2020-07-15 |
| BR112019011743A2 (pt) | 2019-10-22 |
| AU2017371467B2 (en) | 2023-06-01 |
| WO2018106107A1 (en) | 2018-06-14 |
| IL267114B2 (en) | 2024-08-01 |
| ZA201906473B (en) | 2020-07-29 |
| MA51978A (fr) | 2021-01-20 |
| JP7264813B2 (ja) | 2023-04-25 |
| IL267114B1 (en) | 2024-04-01 |
| AU2017371467A1 (en) | 2019-07-25 |
| CA3046055A1 (en) | 2018-06-14 |
| US11285099B2 (en) | 2022-03-29 |
| PH12019550093A1 (en) | 2020-02-10 |
| CL2019001550A1 (es) | 2020-02-28 |
| JP2020500915A (ja) | 2020-01-16 |
| EA201991341A1 (ru) | 2019-12-30 |
| EP3551166B1 (en) | 2024-08-21 |
| IL267114A (en) | 2019-08-29 |
| FI3551166T3 (fi) | 2024-10-04 |
| EP3551166A1 (en) | 2019-10-16 |
| US20200276106A1 (en) | 2020-09-03 |
| UA125040C2 (uk) | 2021-12-29 |
| CN110248644A (zh) | 2019-09-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019550093A1 (en) | Topical phenytoin for use in the treatment of peripheral neuropathic pain | |
| PH12015502310B1 (en) | Pharmaceutical composition, methods for treating and uses thereof | |
| BR112019007798A2 (pt) | veículo de liberação oral | |
| TN2017000554A1 (en) | Novel combination for use in the treatment of cancer | |
| NZ700881A (en) | Compositions and methods comprising celecoxib or related compounds and dextromethorphan | |
| WO2015023976A3 (en) | Selective grp94 inhibitors and uses thereof | |
| MX337454B (es) | Composicion acuosa que contiene bromhexina. | |
| BR112015016997A2 (pt) | composto, composição farmacêutica e método para o tratamento ou prevenção de câncer de mama | |
| BR112014017716A8 (pt) | composições de ésteres de forbol, métodos para prevenir ou tratar acidente vascular cerebral e uso de ésteres de forbol | |
| MX2010014041A (es) | Una forma cristalina de posaconazol. | |
| NZ712270A (en) | Pharmaceutical composition of s-ketamine hydrochloride | |
| NZ702087A (en) | Pharmaceutical compositions and treatment of mastitis | |
| MX340985B (es) | Compuestos de n-heteroarilo. | |
| MX2022001796A (es) | Metodos y composiciones para inhibir los sintomas asociados con la veisalgia. | |
| BR112019001602A2 (pt) | composição de açúcar | |
| WO2014071168A3 (en) | Administering inhibitors of tgfbeta signaling to improve muscle function in cancer patients | |
| MX2015009348A (es) | Composiciones hemostaticas. | |
| MX2015011588A (es) | Tratamiento de combinacion. | |
| BR112015004452A2 (pt) | sirna e seu uso em métodos e composições para o tratamento e/ou prevenção de condições oculares | |
| MX354614B (es) | Composición farmacéutica de diosmina y hesperidina y su uso en dolor neuropático. | |
| MX2018015240A (es) | Composiciones que comprenden timolol y su uso en el tratamiento de rosacea mediante administracion topica. | |
| MX2016013108A (es) | Nueva composicion para el tratamiento de la tricomoniasis. | |
| MX2015013911A (es) | Combinacion sinergistica de paracetamol/celecoxib para el tratamiento de dolor inflamatorio. | |
| WO2014195900A3 (es) | Composiciones farmacéuticas orales para uso en dislipidemias | |
| BR112014015193A8 (pt) | composição enriquecida com glicoproteína como um aditivo para alimento e/ou ração e/ou como um agente terapêutico |